Device Week – Mar. 17, 2017
Executive Summary
On this week's Medtech Insight podcast: President Trump releases budget "blueprint" calling for cuts in many US agencies, including FDA; class II designations formalized by FDA for a slew of important products; FDA proposes exempting from 510(k) requirements hundreds of class II devices; a new surgical robotic project wins a €4m grant from European Commission; an update from the American College of Cardiology annual scientific sessions.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.